Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting...
Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards
Vaccinex announces Nasdaq delisting due to non-compliance with equity standards; trading shifts to OTC Markets.Quiver AI SummaryVaccinex, Inc., a clinical-stage biotechnology company focused on treating...
Vaccinex, Inc. Reports Q3 Financial Results and Advances Alzheimer’s Development While Exploring Partnership Opportunities
Vaccinex reports promising Alzheimer’s treatment results, financial updates, and plans for partnerships to enhance development.Quiver AI SummaryVaccinex, Inc. has reported its financial results for the...